Hospital
MRH Corp.
MRH Corp. was paid $3.71M by Medicaid between Jan 2018 and Dec 2024, across 268 billing codes. Its largest line is 99285, emergency room visit (most serious) — 12% of everything it billed.
33Billing provider infoMRH CORP.
DOVER FOXCROFT, ME 04426
DOVER FOXCROFT, ME 04426
33aNPI1558319103assigned 05/05/2006
33bProvider typeCritical Access Hospital
28Total paid$3.71M
24GClaims592,339
24DCodes billed268
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#3 of 14
Median peer was paid$1.76M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,876 | $461K | |
| 2019 | 90,939 | $556K | |
| 2020 | 80,611 | $489K | |
| 2021 | 88,352 | $514K | |
| 2022 | 80,699 | $485K | |
| 2023 | 96,333 | $615K | |
| 2024incomplete | 71,529 | $588K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 10,434 | 7,797 | $456K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 2,816 | 2,601 | $397K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.5% | 14,905 | 11,306 | $204K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.5% | 31,051 | 20,156 | $203K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 2,944 | 2,632 | $188K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 4.6% | 4,838 | 4,247 | $172K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.1% | 1,042 | 1,003 | $150K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.5% | 4,614 | 3,958 | $130K |
| A0425 | Ground mileage, per statute mile | 3.0% | 12,589 | 9,208 | $111K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.9% | 28,043 | 9,110 | $106K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.8% | 4,334 | 3,902 | $104K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 5,120 | 3,719 | $97K |
256 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 2.4% | 22,713 | $91K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 9,554 | $67K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 6,871 | $63K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 4,357 | $62K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 3,947 | $60K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 5,769 | $55K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.2% | 415 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 9,748 | $41K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 432 | $40K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 18,328 | $40K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 1.1% | 2,081 | $39K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,164 | $36K |
| 80053 | Comprehensive metabolic panel | <1% | 28,480 | $34K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,739 | $33K |
| G0378 | Hospital observation service, per hour | <1% | 478 | $30K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,764 | $28K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 908 | $27K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,931 | $26K |
| 20610 | <1% | 2,173 | $22K | |
| 72100 | <1% | 1,276 | $22K | |
| 90837 | Psychotherapy session, about an hour | <1% | 4,098 | $21K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 264 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,915 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,504 | $19K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,849 | $19K |
| 73564 | <1% | 1,224 | $18K | |
| 73030 | <1% | 1,089 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,904 | $15K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,282 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 444 | $14K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,860 | $12K |
| 99442 | <1% | 1,276 | $11K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,187 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,742 | $10K |
| 73630 | <1% | 809 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,335 | $10K |
| 83735 | <1% | 13,011 | $9K | |
| 76830 | Ultrasound, transvaginal | <1% | 510 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,714 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,358 | $8K |
| 84484 | <1% | 6,223 | $8K | |
| 73610 | <1% | 684 | $8K | |
| 96376 | <1% | 1,451 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 132 | $7K |
| 83880 | <1% | 2,740 | $7K | |
| 76641 | <1% | 332 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,304 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 39,213 | $6K |
| 71250 | <1% | 80 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 106 | $6K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,136 | $6K |
| 73502 | <1% | 280 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,488 | $6K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 84 | $5K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 187 | $5K |
| 51798 | <1% | 283 | $5K | |
| 87040 | <1% | 2,456 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,030 | $4K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 2,766 | $4K |
| 80306 | <1% | 4,013 | $4K | |
| 93971 | <1% | 97 | $4K | |
| 82607 | <1% | 3,027 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,856 | $4K |
| 96367 | <1% | 452 | $4K | |
| 97162 | <1% | 376 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,507 | $4K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 214 | $4K |
| 93017 | <1% | 88 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,853 | $3K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 493 | $3K |
| 82728 | <1% | 2,645 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 71 | $3K |
| 82803 | <1% | 2,104 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 533 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 580 | $3K |
| 71271 | <1% | 283 | $3K | |
| 83605 | <1% | 3,273 | $3K | |
| 99443 | <1% | 206 | $2K | |
| 80061 | Lipid panel | <1% | 9,251 | $2K |
| 84439 | <1% | 1,855 | $2K | |
| 87077 | <1% | 2,901 | $2K | |
| 82570 | <1% | 2,170 | $2K | |
| 82043 | <1% | 1,922 | $2K | |
| 73130 | <1% | 212 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,461 | $2K |
| 85610 | <1% | 6,243 | $2K | |
| 85027 | <1% | 1,795 | $2K | |
| 93225 | <1% | 75 | $2K | |
| 82948 | <1% | 2,808 | $1K | |
| 87631 | <1% | 1,595 | $1K | |
| 81015 | <1% | 5,355 | $1K | |
| 83690 | <1% | 4,257 | $1K | |
| 83550 | <1% | 2,081 | $1K | |
| 86140 | <1% | 3,855 | $1K | |
| 87168 | <1% | 1,472 | $1K | |
| 73221 | <1% | 38 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,467 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,024 | $1K |
| 76775 | <1% | 42 | $1K | |
| 83037 | <1% | 332 | $1K | |
| 83540 | <1% | 2,657 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 348 | $1K |
| 97161 | <1% | 116 | $1K | |
| 73110 | <1% | 133 | $1K | |
| 81003 | <1% | 8,684 | $1K | |
| 86803 | <1% | 998 | $1K | |
| 85379 | <1% | 2,048 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,252 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 133 | $999.66 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 389 | $998.91 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 172 | $941.96 |
| 85651 | <1% | 2,198 | $904.82 | |
| 76536 | <1% | 51 | $889.19 | |
| 85730 | <1% | 1,594 | $850.89 | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,202 | $805.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 420 | $801.95 |
| J3490 | Unclassified drugs | <1% | 312 | $793.91 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,619 | $792.19 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 21 | $692.55 |
| 82077 | <1% | 847 | $640.70 | |
| 97602 | <1% | 68 | $609.13 | |
| 82746 | <1% | 586 | $571.30 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,724 | $570.36 |
| 74018 | <1% | 53 | $530.15 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 250 | $523.41 |
| 85007 | <1% | 1,351 | $486.30 | |
| A0434 | Specialty care transport (sct) | <1% | 27 | $481.09 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 102 | $463.69 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 30 | $461.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,171 | $455.92 |
| 77066 | Tomosynthesis, mammo | <1% | 24 | $445.95 |
| 95251 | <1% | 267 | $438.24 | |
| 86850 | <1% | 260 | $427.29 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 133 | $397.15 |
| 77065 | Tomosynthesis, mammo | <1% | 24 | $383.32 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 362 | $373.00 |
| 36600 | <1% | 65 | $322.95 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,562 | $317.22 |
| 51702 | <1% | 16 | $308.17 | |
| 87081 | <1% | 2,887 | $302.57 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 442 | $290.78 |
| 81025 | <1% | 3,411 | $279.30 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 132 | $273.84 |
| 94010 | <1% | 14 | $273.56 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 119 | $255.04 |
| 95806 | <1% | 14 | $244.59 | |
| 82550 | <1% | 464 | $228.69 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 222 | $214.05 |
| 94727 | <1% | 13 | $213.17 | |
| 87205 | <1% | 1,341 | $212.20 | |
| 80305 | <1% | 2,642 | $209.79 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 21 | $207.52 |
| 86900 | <1% | 185 | $206.56 | |
| 86901 | <1% | 185 | $201.57 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 482 | $191.30 |
| 72070 | <1% | 12 | $178.80 | |
| 87430 | <1% | 1,318 | $177.81 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 741 | $177.26 |
| 90849 | <1% | 317 | $162.60 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 71 | $157.69 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,242 | $151.87 |
| 81002 | <1% | 1,850 | $147.93 | |
| 84550 | <1% | 192 | $146.18 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 87 | $137.40 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 86 | $133.04 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 577 | $128.17 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 51 | $120.00 |
| 97035 | <1% | 95 | $118.65 | |
| 86618 | <1% | 109 | $118.58 | |
| 82150 | <1% | 552 | $118.06 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 25 | $113.12 |
| 80320 | <1% | 141 | $100.25 | |
| 97166 | <1% | 14 | $93.31 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 982 | $91.48 |
| 93016 | <1% | 90 | $91.22 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 416 | $87.58 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 134 | $86.08 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 424 | $79.05 |
| 93018 | <1% | 89 | $76.96 | |
| 77080 | <1% | 53 | $76.89 | |
| 83615 | <1% | 107 | $74.28 | |
| G0008 | Administration of influenza virus vaccine | <1% | 31 | $72.11 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,090 | $67.45 |
| 87070 | <1% | 143 | $67.21 | |
| 84156 | <1% | 93 | $64.00 | |
| 98968 | <1% | 39 | $60.80 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 689 | $58.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,331 | $54.51 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 198 | $51.26 |
| 87186 | <1% | 270 | $46.37 | |
| 84100 | <1% | 48 | $46.29 | |
| 84702 | <1% | 376 | $43.48 | |
| 85018 | <1% | 105 | $41.04 | |
| 84403 | <1% | 27 | $39.91 | |
| 99441 | <1% | 26 | $39.84 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 21 | $38.42 |
| 80076 | <1% | 145 | $36.38 | |
| 99459 | <1% | 24 | $35.61 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 863 | $33.89 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 278 | $28.77 |
| 81001 | <1% | 775 | $26.52 | |
| 80074 | <1% | 16 | $26.11 | |
| 82652 | <1% | 89 | $23.35 | |
| 59025 | Fetal non-stress test | <1% | 422 | $21.51 |
| 90662 | <1% | 15 | $18.01 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 64 | $16.86 |
| 86703 | <1% | 58 | $16.61 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 55 | $15.42 |
| 80143 | <1% | 62 | $15.23 | |
| 87275 | <1% | 305 | $11.36 | |
| 87276 | <1% | 305 | $11.36 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 178 | $10.97 |
| 82947 | <1% | 177 | $9.55 | |
| 85014 | <1% | 116 | $8.86 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 20 | $7.55 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 15 | $7.50 |
| 82272 | <1% | 12 | $6.71 | |
| 85045 | <1% | 18 | $6.58 | |
| 80069 | <1% | 14 | $6.56 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 230 | $5.15 |
| A9270 | Non-covered item or service | <1% | 1,001 | $4.10 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 18 | $3.52 |
| 80179 | <1% | 43 | $3.33 | |
| 90674 | <1% | 14 | $1.36 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 152 | $0.66 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $0.49 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 21 | $0.19 |
| 87660 | 0% | 261 | $0.00 | |
| 82565 | 0% | 27 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 453 | $0.00 |
| 0002A | 0% | 30 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 73140 | 0% | 13 | $0.00 | |
| 80164 | 0% | 14 | $0.00 | |
| 83970 | 0% | 16 | $0.00 | |
| 82140 | 0% | 15 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 18 | $0.00 |
| 83655 | 0% | 39 | $0.00 | |
| 91300 | 0% | 66 | $0.00 | |
| 84481 | 0% | 13 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 86787 | 0% | 26 | $0.00 | |
| 86038 | 0% | 18 | $0.00 | |
| 84146 | 0% | 12 | $0.00 | |
| 87340 | 0% | 12 | $0.00 | |
| 87807 | 0% | 232 | $0.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 74 | $0.00 |
| 86592 | 0% | 41 | $0.00 | |
| 90686 | 0% | 35 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 68 | $0.00 |
| 0001A | 0% | 33 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 86430 | 0% | 14 | $0.00 | |
| 84153 | 0% | 12 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLARK, RANDALL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Sebasticook Valley Health | Pittsfield, ME | $3.69M |
| Sebasticook Valley Health | Pittsfield, ME | $2.82M |
| Sebasticook Valley Health | Unity, ME | $1.39M |
| Sebasticook Valley Health | Newport, ME | $1.33M |
| Charles a Dean Memorial Hospital | Greenville, ME | $617K |
| Belle Meade Foundation INC | Richmond, MI | $172K |
| Riverwood Family Medicine PC | Grand Rapids, MI | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.